Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Anguilla Healthcare Digest.
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
Press releases published on May 13, 2025
AVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today
GlobeNewswire
·
May 13, 2025
VALENCIA, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, is hosting its Acute Wound Care Showcase 2025 virtually today, May 13, 2025 …
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
GlobeNewswire
·
May 13, 2025
– Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 – – On track to initiate similarly-designed Phase 2 study in patients with COPD imminently – SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited ( …
Doheny Eye Institute Announces Kaustabh Ghosh, Ph.D. as the Mary D. Allen Endowed Chair in Vision Research
GlobeNewswire
·
May 13, 2025
PASADENA, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions for more than 75 years, is proud to announce that Kaustabh Ghosh, Ph.D., has been awarded the Mary D. Allen Endowed Chair in …
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
GlobeNewswire
·
May 13, 2025
Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of engineered effector T cells Data Shared at 2025 Annual Meeting of American Association of Immunologists MIRAMAR, Fla., May 13, 2025 (GLOBE …
Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements
GlobeNewswire
·
May 13, 2025
20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025 35 new accounts and …
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
GlobeNewswire
·
May 13, 2025
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes …
Burn Care Market worth US$3.35 billion by 2030 with 5.6% CAGR | MarketsandMarkets™
GlobeNewswire
·
May 13, 2025
Delray Beach, FL, May 13, 2025 (GLOBE NEWSWIRE) -- The global burn care market, valued at US$2.46 billion in 2024, is forecasted to grow at a robust CAGR of 5.6%, reaching US$2.55 billion in 2025 and an impressive US$3.35 billion by 2030. This market is …
CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
GlobeNewswire
·
May 13, 2025
Survival observations in mTNBC patients correlated with increased PD-L1 expression Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot” VANCOUVER, Washington, May 13, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (" …
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
GlobeNewswire
·
May 13, 2025
Glen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related …
Excision BioTherapeutics Presents Data from HBV and HSV Programs at the ASGCT 2025 Annual Meeting
GlobeNewswire
·
May 13, 2025
Poster presentation to demonstrate EBT-107’s potential to reduce clinically-relevant biomarkers and HBV DNA integration toward functional remission of chronic hepatitis B Oral presentation to highlight significant reduction in HSC-1 viral load in the …
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
GlobeNewswire
·
May 13, 2025
SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Human …
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
GlobeNewswire
·
May 13, 2025
HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific …
Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101
GlobeNewswire
·
May 13, 2025
- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - - Findings highlight BMB-101’s potential to address critical gaps in SUDEP …
Affimed Announces Filing for the Opening of Insolvency Proceedings
GlobeNewswire
·
May 13, 2025
MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for …
OneMedNet Enhances Data Discovery and Analytics with the Datavant Connect platform and Amazon Web Service (AWS) Clean Rooms
GlobeNewswire
·
May 13, 2025
MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading provider of regulatory-grade imaging Real-World Data (iRWD) today has announced its adoption of expanded capabilities within the …
PBGH Announces Jumbo Employers’ Top 5 Health Care Priorities
GlobeNewswire
·
May 13, 2025
Oakland, California, May 13, 2025 (GLOBE NEWSWIRE) -- Purchaser Business Group on Health (PBGH), a nonprofit coalition representing 40 private employers and public entities across the U.S., announced today the results of its member survey on top health …
VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference
GlobeNewswire
·
May 13, 2025
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon “Poster of Distinction” award at the …
SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury
GlobeNewswire
·
May 13, 2025
DENVER, May 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced …
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
May 13, 2025
Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting …
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
GlobeNewswire
·
May 13, 2025
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, …